MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma

摘要

Background & AimsSorafenib is the standard of care in advanced hepatocellular carcinoma (HCC), however no criteria have been established to select patients likely to benefit from this therapy. In this study, we evaluated the predictive role of microRNAs (miRNAs) in this setting of patients.